Home >> Signaling Pathways >> MAPK Signaling

MAPK Signaling

Targets for  MAPK Signaling

Products for  MAPK Signaling

  1. Cat.No. Product Name Information
  2. GC65949 GNE-9815 GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for CRAF and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers. GNE-9815  Chemical Structure
  3. GC38917 Gossypetin A flavonoid with diverse biological activities Gossypetin  Chemical Structure
  4. GC38791 GSK-25 GSK-25 is a potent, selective and orally bioavailable ROCK1 inhibitor (IC50=7 nM). GSK-25  Chemical Structure
  5. GC60886 GSK356278 A selective PDE4 inhbitor GSK356278  Chemical Structure
  6. GC43798 Guanylyl Imidodiphosphate (lithium salt) Guanylyl imidodiphosphate (Gpp(NH)p) lithium, a non-hydrolyzable GTP analogue, increases adenylate cyclase activity. Guanylyl Imidodiphosphate (lithium salt)  Chemical Structure
  7. GC17658 Guggulsterone Broad spectrum steroid receptor ligand Guggulsterone  Chemical Structure
  8. GC36199 GW284543 GW284543 (UNC10225170) is a selective MEK5 inhibitor. GW284543 reduces pERK5, and decreases endogenous MYC protein. GW284543  Chemical Structure
  9. GC11685 GW5074 C-Raf inhibitor,potent and selective GW5074  Chemical Structure
  10. GC36203 GW806742X GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X  Chemical Structure
  11. GC61454 GW806742X hydrochloride GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis. GW806742X hydrochloride  Chemical Structure
  12. GC63000 Gypenoside L Gypenoside L is a saponin that can be found in Gynostemma pentaphyllum. Gypenoside L  Chemical Structure
  13. GC19396 H 89

    A potent inhibitor of cyclic AMP-dependent protein kinase

    H 89  Chemical Structure
  14. GC10074 H 89 2HCl H 89 2HCl is a potent and selective inhibitor of protein kinase A (PKA) with an IC50 of 48 nM and has weak inhibition on PKG, PKC, Casein Kinase. H 89 2HCl  Chemical Structure
  15. GC12799 H-8 (hydrochloride) H-8 (dihydrochloride) is a cell-permeable, reversible and ATP-competitive PKA inhibitor. H-8 (hydrochloride)  Chemical Structure
  16. GC43803 HA-1077 (hydrochloride) Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an Ki of 0.33 μM for ROCK1, IC50s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. HA-1077 (hydrochloride) is also a potent Ca2+ channel antagonist and vasodilator. HA-1077 (hydrochloride)  Chemical Structure
  17. GN10248 Hesperitin Hesperitin  Chemical Structure
  18. GC36223 HG6-64-1 HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1); has a IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells. HG6-64-1  Chemical Structure
  19. GC12201 HI TOPK 032

    T-LAK-cell-originated protein kinase (TOPK) inhibitor

    HI TOPK 032  Chemical Structure
  20. GC64035 Hirsutenone Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone  Chemical Structure
  21. GN10664 Honokiol Honokiol  Chemical Structure
  22. GC62514 HPK1-IN-3 HPK1-IN-3 is a potent and selective ATP-competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor with an IC50 of 0.25 nM. HPK1-IN-3  Chemical Structure
  23. GC63569 HPK1-IN-4 HPK1-IN-4 (comp 22) is a HPK1 (MAPK41) inhibitor (IC50 of 0.061 nM) as preclinical immunotherapy tool compound. HPK1-IN-4  Chemical Structure
  24. GC63006 HPK1-IN-7 HPK1-IN-7 is a potent, orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) inhibitor (IC50=2.6 nM) with excellent family and kinome selectivity. HPK1-IN-7 shows selectivity against IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 shows robust efficacy against MC38 syngeneic tumor model in combination with anti-PD1. HPK1-IN-7  Chemical Structure
  25. GC63317 HPK1-IN-8 HPK1-IN-8 is an allosteric, inactive conformation-selective inhibitor of full-length HPK1. HPK1-IN-8  Chemical Structure
  26. GC43885 Hypothemycin A resorcylic acid lactone polyketide Hypothemycin  Chemical Structure
  27. GC25521 IMM-H007 IMM-H007, an adenosine derivative, is an activator of AMP-Activated Protein Kinase (AMPK). IMM-H007 is a potential drug for treating cardiac dysfunction. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 (ATP binding cassette subfamily a member 1) degradation and facilitates its cell-surface localization in macrophages, thereby promotes cholesterol efflux. IMM-H007  Chemical Structure
  28. GC12674 IQ 3 Selective JNK3 inhibitor IQ 3  Chemical Structure
  29. GC36327 IQ-1S free acid An inhibitor of NF-κB/AP-1 IQ-1S free acid  Chemical Structure
  30. GC39095 Isoliquiritin apioside Isoliquiritin apioside significantly decreases PMA-induced increases in MMP9 activities and suppresses PMA-induced activation of MAPK and NF-κB. Isoliquiritin apioside auppresseses invasiveness and angiogenesis of cancer cells and endothelial cells. Isoliquiritin apioside  Chemical Structure
  31. GN10023 Isorhamnetin Isorhamnetin  Chemical Structure
  32. GN10804 Isovitexin Isovitexin  Chemical Structure
  33. GC33844 Isovitexin (Saponaretin) A C-glycosylated flavone with diverse biological activities Isovitexin (Saponaretin)  Chemical Structure
  34. GC32209 ITX5061 ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1). ITX5061  Chemical Structure
  35. GC36359 J30-8 J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC50 of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8  Chemical Structure
  36. GC65303 Jaspamycin Jaspamycin (7-CN-7-C-Ino) is a potent activator of PKA, binding to the R site (PKAR), with an EC50 of 6.5 nM and Kd of 8 nM in Trypanosoma brucei. Jaspamycin  Chemical Structure
  37. GC13724 JIP-1 (153-163) Peptide inhibitor of c-Jun N-terminal kinase (JNK) JIP-1 (153-163)  Chemical Structure
  38. GC15028 JNK-IN-7 A non-selective JNK inhibitor JNK-IN-7  Chemical Structure
  39. GC13841 JNK-IN-8 JNK-IN-8 is the first irreversible inhibitor of JNK, targeting JNK1, JNK2, and JNK3 with IC50 values of 4.7 nM, 18.7 nM, and 1 nM, respectively, in the A375 cell line. JNK-IN-8  Chemical Structure
  40. GC32983 Juglanin Juglanin, a natural occurring flavonoid, is a JNK acticator, with inflammation and anti-tumor activities. Juglanin  Chemical Structure
  41. GC38804 JWG-071 JWG-071 is the first reported kinase-selective chemical probe for ERK5. JWG-071 improves ERK5 activity and BRD4 selectivity. JWG-071 will be a much-needed chemical probe for deconvoluting ERK5 and BRD4 pharmacology. JWG-071  Chemical Structure
  42. GC13116 JX 401 p38α inhibitor JX 401  Chemical Structure
  43. GC11362 K 252a A protein kinase inhibitor K 252a  Chemical Structure
  44. GC17702 K-Ras(G12C) inhibitor 9 allosteric inhibitor of oncogenic K-Ras(G12C) K-Ras(G12C) inhibitor 9  Chemical Structure
  45. GC13640 Kemptide substrate for cAMP-dependent protein kinase (PKA) Kemptide  Chemical Structure
  46. GC36391 Kemptide Phospho-Ser5 Kemptide (Phospho-Ser5) is a phosphate acceptor peptide that serves as a specific substrate for cAMP-dependent protein kinase (PKA). Kemptide Phospho-Ser5  Chemical Structure
  47. GC33051 KO-947 An ERK inhibitor KO-947  Chemical Structure
  48. GC14648 KT 5720

    protein kinase A inhibitor, potent and selective

    KT 5720  Chemical Structure
  49. GC17346 KT 5823 A protein kinase G inhibitor KT 5823  Chemical Structure
  50. GC46015 KY 05009 A TNIK inhibitor KY 05009  Chemical Structure
  51. GC15924 L-779,450 Raf kinase inhibitor L-779,450  Chemical Structure
  52. GC44022 L-858,051 (hydrochloride) L-858,051 is a water-soluble analog of forskolin, a cell-permeant activator of adenylate cyclase. L-858,051 (hydrochloride)  Chemical Structure
  53. GC34275 L-JNKI-1 L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK. L-JNKI-1  Chemical Structure
  54. GC44085 L-Sulforaphene L-Sulforaphene, isolated from radish seeds, exhibits an ED50 against velvetleaf seedlings approximately 2 x 10-4 M. L-Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting EGFR, p-ERK1/2, NF‐κB and other signals. L-Sulforaphene  Chemical Structure
  55. GC16576 LGX818 LGX818 (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM). LGX818  Chemical Structure
  56. GC36447 Licochalcone E Licochalcone E, a flavonoid compound isolated from Glycyrrhiza inflate, inhibits NF-κB and AP-1 transcriptional activity through the inhibition of AKT and MAPK activation. Licochalcone E  Chemical Structure
  57. GC17608 Lidocaine Anasthetic and class Ib antiarrhythmic agent Lidocaine  Chemical Structure
  58. GC33831 Lidocaine hydrochloride (Lignocaine hydrochloride) Lidocaine hydrochloride (Lignocaine hydrochloride) (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride (Lignocaine hydrochloride)  Chemical Structure
  59. GC16039 LJH685 RSK (p90 ribosomal S6 kinase) inhibitor LJH685  Chemical Structure
  60. GC16601 LJI308

    pan-RSK inhibitor

    LJI308  Chemical Structure
  61. GC11157 LL-Z 1640-4 A signal-specific JNK/p38 pathway and TAK 1 inhibitor LL-Z 1640-4  Chemical Structure
  62. GC30770 LM22B-10 An activator of TrkB and TrkC LM22B-10  Chemical Structure
  63. GC34650 Longdaysin

    Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC50s of? 5.6 ?M, 8.8 ?M, 29 ?M, and 52 ?M, respectively.

    Longdaysin  Chemical Structure
  64. GC13717 Losmapimod p38 MAPK inhibitor, orally active Losmapimod  Chemical Structure
  65. GN10267 Loureirin B Loureirin B  Chemical Structure
  66. GC19507 LUT-014

    LUT014 is a topical B-Raf Inhibitor

    LUT-014  Chemical Structure
  67. GC19228 LXH254 LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254  Chemical Structure
  68. GC36505 LY-2584702 hydrochloride LY-2584702 hydrochloride is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM. LY-2584702 hydrochloride  Chemical Structure
  69. GC16835 LY2228820 LY2228820 (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. LY2228820  Chemical Structure
  70. GC12089 LY2584702 LY2584702 is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM. LY2584702  Chemical Structure
  71. GC44095 LY2584702 (tosylate) LY2584702 (tosylate) is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM. LY2584702 (tosylate)  Chemical Structure
  72. GC13980 LY3009120

    LY3009120 is a pan-RAF and RAF dimer inhibitor that inhibits all RAF isoforms and occupies both protomers in RAF dimers.

    LY3009120  Chemical Structure
  73. GC19235 LY3214996 LY3214996 (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. LY3214996 potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. LY3214996 shows potent antitumor activities in cancer models with MAPK pathway alterations. LY3214996  Chemical Structure
  74. GC18241 Lysophosphatidylcholines

    Lysophosphatidylcholines are produced by hydrolysis of the fatty acid of phosphatidylcholine at either the sn-1 or sn-2 position by phospholipase A2 (PLA2) or by lecithin-cholesterol acyltranferase (LCAT), which transfers the fatty acid to cholesterol.

    Lysophosphatidylcholines  Chemical Structure
  75. GC31735 Magnolin A lignan with anti-inflammatory and anticancer activities Magnolin  Chemical Structure
  76. GC30545 Malantide Malantide is a synthetic dodecapeptide derived from the site phosphorylated by cAMP-dependent protein kinase (PKA) on the β-subunit of phosphorylase kinase. Malantide is a highly specific substrate for PKA with a Km of 15 μM and shows protein inhibitor (PKI) inhibition >90% substrate phosphorylation in various rat tissue extracts. Malantide is also an efficient substrate for PKC with a Km of 16 μM. Malantide  Chemical Structure
  77. GC63059 MAP4K4-IN-3 MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. MAP4K4-IN-3  Chemical Structure
  78. GC64904 MAP855 MAP855 is a highly potent, selective, ATP-competitive and orally active MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2. MAP855  Chemical Structure
  79. GC30676 MAPK13-IN-1 MPAK13-IN-1 is a MAPK13 (p38δ) inhibitor, with an IC50 of 620 nM. MAPK13-IN-1  Chemical Structure
  80. GC11277 MEK inhibitor MEK inhibitor  Chemical Structure
  81. GC33388 MEK-IN-1 MEK-IN-1 is a MEK inhibitor extracted from patent WO2008076415A1. MEK-IN-1  Chemical Structure
  82. GC12843 MEK162 (ARRY-162, ARRY-438162) MEK162 (ARRY-162, ARRY-438162) (MEK162) is an oral and selective MEK1/2 inhibitor. MEK162 (ARRY-162, ARRY-438162) (MEK162) inhibits MEK with an IC50 of 12 nM. MEK162 (ARRY-162, ARRY-438162)  Chemical Structure
  83. GC33771 Metadoxine Metadoxine blocks adipocyte differentiation in association with inhibition of the protein kinase A-cAMP response element binding protein (PKA-CREB) pathway. Metadoxine  Chemical Structure
  84. GC49241 Methyl Diethyldithiocarbamate An active metabolite of disulfiram Methyl Diethyldithiocarbamate  Chemical Structure
  85. GC36596 Methylnissolin Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC50 of 10 μM. Methylnissolin  Chemical Structure
  86. GC16007 Methylthiouracil antithyroid preparation Methylthiouracil  Chemical Structure
  87. GC44211 MK2 Inhibitor III MK2 Inhibitor III (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM. MK2 Inhibitor III  Chemical Structure
  88. GC16723 MK2 Inhibitor IV MK2 Inhibitor IV is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode. MK2 Inhibitor IV  Chemical Structure
  89. GC33142 MK2-IN-1 (MK2 Inhibitor) MK2-IN-1 (MK2 Inhibitor) is a potent and selecitve MAPKAPK2(MK2) inhibitor(IC50=0.11 uM) with a non-ATP competitive binding mode. MK2-IN-1 (MK2 Inhibitor)  Chemical Structure
  90. GC61819 MK2-IN-3 MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC50 of 8.5 nM. MK2-IN-3  Chemical Structure
  91. GC18156 MK8353

    Selective and orally available ERK1/2 inhibitor

    MK8353  Chemical Structure
  92. GC62315 MKK7-COV-9 MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM. MKK7-COV-9  Chemical Structure
  93. GC15296 ML 786 dihydrochloride Raf kinase inhibitor ML 786 dihydrochloride  Chemical Structure
  94. GC11307 ML-264 Krüppel-like factor 5 (KLF5) inhibitor ML-264  Chemical Structure
  95. GC49440 ML-9 A PKB/Akt inhibitor ML-9  Chemical Structure
  96. GC64634 MLK-IN-1 MLK-IN-1 is a potent, brain penetrant and specific mixed lineage kinase 3 (MLK-3) inhibitor, compound 68, extracted from patent US20140256733A1. MLK-IN-1  Chemical Structure
  97. GC63680 MLKL-IN-2 MLKL-IN-2 is a MLKL inhibitor extracted from patent WO2021224505A1, compound (i). MLKL-IN-2  Chemical Structure
  98. GC11649 MLN 2480 An oral pan-Raf kinase inhibitor MLN 2480  Chemical Structure
  99. GC64580 MMI-0100 MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100  Chemical Structure
  100. GC48469 Moexipril-d5 An internal standard for the quantification of moexipril Moexipril-d5  Chemical Structure
  101. GC32789 Mogrol Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling. Mogrol  Chemical Structure

Items 201 to 300 of 498 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction